Dallas, TX: ReportsandReports announce it will carry Commercial Insight: Antihormonal Cancer Therapies – Leading brands strive to minimize generic sales erosion Market Research Report in its Store. Browse complete Commercial Insight: Antihormonal Cancer Therapies – Leading brands strive to minimize generic sales erosion Report Introduction Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and prostate cancer. The high incidence of these tumor types translates into a significant commercial potential for drug developers. Collectively, the antihormonal therapy cancer brands generated sales of about $7.0 billion in the seven major pharmaceutical markets in 2009. Scope * In-depth analysis of the current and future antihormonal therapies market across the US, 5EU and Japan, plus a rest of world snapshot * Antihormonal therapy sales forecasts for brands and generics from 2009 to 2019 * Assessment of the leading cancer brands and drug classes to identify key success factors within this sector * Evaluation of the strategies of leading players in the antihormonals market Highlights The antihormonals market was worth $7.0 billion in 2009 across the seven major pharmaceutical markets. Datamonitor forecasts the antihormonals market will shrink marginally in the forecast period 20092019, at a CAGR of negative 0.7%. In 2019 the top three brands in terms of forecast sales will be Arimidex, Lupron (leuprolide; Takeda/Abbott) and Casodex (bicalutamide; AstraZeneca). Despite losing around 54% of its current sales value to generic competitors, Arimidex will retain its market leading position. In a mature market, the importance of product lifecycle management is high. AstraZeneca was the key player in the market in 2009, with an antihormonals portfolio valued at over $3.2 billion. With successful lifecycle management and a considerable investment in marketing activities, AstraZeneca has built a strong brand presence for its products. Reasons to Purchase * Quantify the performance of each of the marketed antihormonal therapy cancer brands in the seven major markets over the period 2009 to 2019 * Acquire a detailed account of antihormonal therapy cancer brand dynamics and the events that drive and limit their market growth * Benchmark antihormonal therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot Table Of Contents Overview Catalyst Summary About Datamonitor healthcare About the Oncology pharmaceutical analysis team EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor insight into the antihormonal cancer therapies market Related reports Upcoming related reports Table of Contents MARKET DEFINITION Definition of the cancer market Antihormonal therapies by ATC class L2A3 – Luteinizing hormone-releasing hormone agonists L2B1 – Anti-estrogens L2B2 – Anti-androgens L2B3 – Aromatase inhibitors L2B9 – Other hormone antagonists MARKET OVERVIEW Seven major markets Current and future market overview The antihormonals market will shrink marginally in the forecast period Patent expiries of leading antihormonal brands are set to occur within the next 5 years The US will suffer the greatest impact of generic erosion, losing around 25% of its value over the forecast period The aromatase inhibitors will continue to be the leading drug class in 2019 The current leading antihormonal brands will suffer generic sales erosion but will maintain a high level of sales The antihormonal therapies market will shrink from $7.0 billion in 2009 to $6.5 billion in 2019 across the seven major pharmaceutical markets Opportunities and threats Opportunity 1: aging population will result in increasing cancer incidence Opportunity 2: oncology therapy sales continue to experience strong growth Opportunity 3: high levels of unmet need Threat 1: Pharma’s transition towards specialist secondary care indications may further competition in the oncology market Threat 2: the cost of drug development continues to rise Threat 3: ongoing cost-containment measures US Current and future market assessment The US antihormonals market will suffer the greatest impact of generic sales erosion Opportunities and threats Opportunity 1: the US’s large population and high healthcare expenditure will continue to offer commercial opportunities for drug developers Opportunity 2: healthcare reform will boost the number of insured in the US Opportunity 3: closure of the Medicare Part D coverage gap is good news for branded Pharma Threat 1: growing regulatory pressures increase costs and decrease market penetration for Pharma Threat 2: patent expiries and the resulting generic competition will erode branded sales revenues Threat 3: the US health reform law will intensify cost-containment pressures Japan Current and future market assessment The antihormonals market in Japan is forecast to grow over the forecast period Opportunities and threats Opportunity 1: the aging population represents a large and growing patient base Opportunity 2: generic sales erosion remains low in Japan Opportunity 3: decrease in lag times for launch of new drugs could accelerate new launches Threat 1: government-enforced biennial cuts continue to have a negative effect on market growth Threat 2: healthcare proposal to change current pricing system will be of limited benefit to Japanese Pharma Threat 3: encouraging decrease in lag times for launch of new drugs Five major European markets (5EU) Current and future market assessment The antihormonals therapies market in the five European countries will show marginal growth The antihormonal therapies market will grow from $2.6 billion in 2009 to $2.7 billion in 2019 in the five major European markets Opportunities and threats Opportunity 1: EU Cancer Task Force will improve the availability of information while generating funds for research Opportunity 2: reorganization of the European Medicines Agency (EMA) expected to streamline EU regulatory process Threat 1: new European drug price reductions are likely to affect pharma industry growth Threat 2: higher generic uptake in less mature EU markets will impact branded sales revenues Threat 3: EC inquiry into delays in generics market entry will have wide-ranging ramifications for the branded and generics industry Threat 4: Spain’s price cuts and reference groups are driving drug prices down Threat 5: new low reimbursement rate created in France signals the growing pressure for cost-containment Threat 6: NICE will remain a significant hurdle to commercialization of cancer drugs in the UK, despite relaxation of its cost-effectiveness criteria Threat 7: Germany’s new cost-effectiveness analysis system could add to the downward pressure on drug prices Threat 8: additional cuts to the price of oncology drugs in Italy are impending under its pay-for-performance scheme France Current and future market assessment The antihormonal therapies market in France will peak at around $654m in 2010. Germany Current and future market assessment The antihormonals therapies market will grow from $727m in 2009 to $835m in 2019 in Germany Italy Current and future market assessment The antihormonal therapies market will grow from $484m in 2009 to $512m in 2019 in Italy Spain Current and future market assessment The antihormonals market in Spain will marginally shrink from $418m in 2009 to $396m in 2019 in Spain UK Current and future market assessment The antihormonal therapies market will grow from $333m in 2009 to $348m in 2019 in the UK Rest of the world snapshot Current market assessment Rest of the world sales represent 18% of the global antihormonals market Opportunities and threats Opportunity 1: incidence of cancer is forecast to increase in the BRIC countries Opportunity 2: emerging markets continue to attract pharma companies despite challenges Threat 1: cost of new therapies is a barrier to market penetration BRAND DYNAMICS Overview of competitive landscape Arimidex, Lupron and Casodex will be the top three antihormonal brands in 10 years time Drivers of brand choice Efficacy and toxicity are the most important drivers of brand choice Trends in marketing strategies Marketing strategy for leading brands Patient information and support programs Direct-to-consumer advertising Arimidex (anastrozole; AstraZeneca) Drug profile Product positioning SWOT analysis Brand forecast to 2019 Arimidex set to lose 54% of its current sales value to generic competitors Lupron (leuprolide; Takeda/Abbott) Drug profile Product positioning SWOT analysis Brand forecast to 2019 Lupron will be the top selling antihormonal therapy in 2019, with sales in excess of $1 billion Casodex (bicalutamide; AstraZeneca) Drug profile Product positioning SWOT analysis Brand forecast to 2019 Patent expiries set to hamper sales of this class-leading brand KEY DEVELOPERS Strategic overview Trends in corporate strategy Strategic lifecycle management is essential in the antihormonals market Commercialization partnerships are common for smaller players AstraZeneca Corporate strategy Oncology antihormonals portfolio assessment Takeda Corporate strategy Oncology antihormonals portfolio assessment Portfolio assessment of other leading companies BIBLIOGRAPHY Journal papers Websites Datamonitor reports Other APPENDIX A – MARKET ASSUMPTIONS Forecasting assumptions New product launches Patent expiries Data definitions, limitations and assumptions Standard units Country group definitions Rest of the World The ‘all other EU countries’ group The ‘Other non-EU countries’ group Forecast methodology Derivation of sales forecasts and pricing trends Exchange rates Report methodology APPENDIX B About Datamonitor About Datamonitor Healthcare About the Oncology analysis team Disclaimer Browse complete Commercial Insight: Antihormonal Cancer Therapies – Leading brands strive to minimize generic sales erosion Report Browse all Healthcare Market Research Reports Browse all Datamonitor Market Research Reports Browse all Latest Report Related Reports: Commercial Insight: Antihormonal Cancer Therapies Commercial Insight: Molecular Targeted Cancer Therapies About Us: Contact:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
Commercial Insight: Antihormonal Cancer Therapies - Leading brands strive to minimize generic sales erosion now available at ReportsandReports
Posted by
Unknown
on